REGISTERED CHARITY NUMBER: 290959

REPORT OF THE TRUSTEES AND

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

FOR

BRITISH GYNAECOLOGICAL CANCER SOCIETY

BRITISH GYNAECOLOGICAL CANCER SOCIETY

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

	Page
Report of the Trustees	1 to 7
Independent Examiner's Report	8
Statement of Financial Activities	9
Balance Sheet	10
Cash Flow Statement	11
Notes to the Cash Flow Statement	12
Notes to the Financial Statements	13 to 19

The trustees present their report with the financial statements of the charity for the year ended 31 December 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

The objects of the charity are to advance the science and art of gynaecological oncology for the benefit of the public.
The British Gynaecological Cancer Society (BGCS) seeks to achieve these objectives by:
- Making grants to individuals and supporting research in gynaecological oncology.
- Sponsoring and undertaking research relevant to the prevention, diagnosis and treatment of gynaecological cancers.
- Providing advocacy, professional advice and information.
- Running consensus processes and meetings on important areas of gynaecological cancer care.
- Developing and publishing clinical guidelines for the diagnosis and management of gynaecological cancers.
- Working with the Royal College of Obstetricians and Gynaecologists (RCOG) and other professional organisations to support the development of training curricula and surgical skills.
- Supporting the professional development of members and the wider multidisciplinary workforce involved in gynaecological cancer care.
- Acting as an umbrella and resource body for professionals involved in gynaecological oncology.
- Supporting an annual scientific meeting addressing important developments in gynaecological oncology.
- Awarding prizes for high-quality scientific work presented at the Annual Scientific Meeting.
- Supporting trainees and subspeciality fellows through educational activities, research grants and other opportunities.

Public benefit

The trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning future activities.

The trustees consider that the Society's activities provide public benefit by promoting education, research, professional development and improvements in the quality of care provided to people affected by gynaecological cancers.

ACHIEVEMENTS AND PERFORMANCE

Charitable Activities

The BGCS continued to develop and expand during 2025, reflecting the increasing breadth of the Society's activities and its membership across the multidisciplinary professions involved in gynaecological cancer care.
The principal aims of the BGCS remain to advocate for high-quality gynaecological cancer services, promote education and research, support the healthcare professionals involved in delivering these services, and encourage best practice in the diagnosis, treatment and care of people affected by gynaecological cancer.

Annual Scientific Meeting

The 2025 BGCS Annual Scientific Meeting was held in London and was a successful scientific and educational meeting. It attracted 565 delegates, with presentations from national and international speakers covering a broad range of developments in gynaecological cancer.
The meeting returned a small financial surplus.
The British Association of Gynaecological Pathologists (BAGP) held a parallel meeting alongside the BGCS Annual Scientific Meeting. This further strengthened the alliance between the two organisations and encouraged closer multidisciplinary collaboration between gynaecological oncologists and specialist gynaecological pathologists.
The next BGCS Annual Scientific Meeting is planned to take place in Bristol in June 2026.

Trainees and subspecialty fellows

Supporting the next generation of gynaecological oncologists remains a major priority for the Society.
The BGCS held a successful meeting in January 2025 specifically for trainees and gynaecological oncology subspecialty fellows. The meeting provided educational, professional development and networking opportunities and enabled trainees to discuss issues relevant to their training and future careers.
The Society continues to support subspecialty fellows and maintains close links with the Royal College of Obstetricians and Gynaecologists in relation to subspecialty training.
The BGCS is conscious that there are currently a significant number of consultant vacancies within UK gynaecological oncology services and that appropriate workforce planning and the training of sufficient numbers of future consultants are important to maintaining high-quality gynaecological cancer services. The BGCS subspecialty group therefore continues to liaise closely with the RCOG to assist with decision-making and workforce planning in this area.

Unit gynaecologists

The Society held a successful meeting in Birmingham for Unit Gynaecologists with a Special Interest in Gynaecological Cancer.
Supporting clinicians working in cancer units remains an important part of the Society's work. These meetings facilitate education, communication between cancer units and cancer centres, dissemination of best practice and discussion of the particular challenges faced by clinicians managing patients with gynaecological cancer outside specialist cancer centres.

Research grants

The BGCS continues to provide financial support for gynaecological cancer research and to encourage research activity amongst trainees and other members of the Society.
During the year, the Society offered research grants to trainees and other eligible applicants. These included grants administered directly by the BGCS as well as collaborative grants with Wellbeing of Women.
Applications for BGCS research support continue to demonstrate the importance of providing opportunities for trainees and other researchers to develop research projects in gynaecological cancer.

Collaboration with gynaecological cancer charities

The BGCS continues to work closely with charities representing and supporting people affected by gynaecological cancers.
Regular meetings are held with other gynaecological cancer charities to ensure that important issues affecting patients and gynaecological cancer services can, where appropriate, be addressed nationally in a coordinated and cohesive manner.
Organisations participating in these discussions have included Wellbeing of Women, The Eve Appeal, Peaches Womb Cancer Trust, Target Ovarian Cancer, Ovacome and Ovarian Cancer Action.
These relationships provide an important mechanism for ensuring that the professional perspective of the BGCS is informed by the experiences and priorities of patients and the organisations representing them.
Clinical guidelines and consensus development

The BGCS Guidelines Group continued its work during 2025 on the development and revision of clinical guidelines, including the Society's cervical cancer guidelines.
The development of evidence-based guidelines remains a core activity of the Society and supports the BGCS objective of promoting consistent, high-quality care for patients with gynaecological cancer throughout the UK.
The Society also initiated a Delphi consensus process concerning the introduction and use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
The purpose of this process is to establish expert consensus concerning the appropriate introduction and delivery of HIPEC and to provide guidance for clinicians and services considering its implementation. The Society anticipates that the resulting consensus statement will be completed and announced during 2026.

Surgical Skills Project
During the year, the BGCS collaborated with the Royal College of Obstetricians and Gynaecologists and other relevant professional societies on a Surgical Skills Project.
The project seeks to identify the surgical skills and training requirements that will be necessary for future generations of gynaecological surgeons and to consider how appropriate surgical training can be delivered in the context of changing clinical practice, technology and workforce requirements.
The BGCS considers maintenance and development of high-quality surgical training to be fundamental to the future provision of safe and effective gynaecological cancer surgery and will continue to contribute to this work.

Endometrial cancer audit
The national endometrial cancer audit, undertaken in collaboration with the National Disease Registration Service (NDRS/NCRAS), Peaches Womb Cancer Trust, The Eve Appeal and the British Association of Gynaecological Pathologists, published the first report.
The audit represents an important piece of work examining the management of endometrial cancer and provides information that can be used to understand variation in practice and identify opportunities to improve the quality and consistency of care.
Following the successful completion of this work, the BGCS is seeking funding to undertake a similar national audit of vulval cancer.

International Gynaecological Cancer Society
The BGCS has maintained a relationship with the International Gynaecological Cancer Society (IGCS), following the strategic alliance established previously.
In light of the development of the BGCS and the changing requirements of its membership, the Society has decided to review its relationship with the IGCS. This review will consider the benefits provided to BGCS members, opportunities for international education and collaboration, and whether the current arrangements continue to represent an appropriate use of the Society's resources.
Any future arrangements will be determined following completion of this review.

FINANCIAL REVIEW

Financial position
The charity incurred a net deficit over income of £110,721 in the year (2024: a net deficit of £89,376), there was a deficit of £97,361 on unrestricted funds and a net deficit of £13,360 on restricted funds.

As at 31/12/2025 the unrestricted funds stood at £435,502 (2024: £532,863) and restricted funds stood at £nil (2024: £13,360) and this included bank balances of £421,558 (2024: £515,278).

The trustees consider the financial position of the charity to be satisfactory.

FINANCIAL REVIEW

Reserves policy

The Treasurer will monitor the financial reserves of the charity and is responsible for recommending a reserves policy which will be reviewed by the Trustees on an annual basis. The current reserves policy was agreed at the council meeting in June 2017 and is based on the following principals:

-The BGCS should keep reserves that can sustain the working of the charity for a year.

-The BGCS should not keep reserves that are excessive. Assuming the requirement for maintaining reserves for one year is met, the charity should avoid keeping reserves greater than 80% of the sum of the annual income and expenditure averaged over five years

-When reserves are excessive, the charity should explore new avenues of charitable activity.

Under the current reserves policy reserves at the year end continue to be high despite planned expenditure on funding the feasibility pilot of a National Endometrial Cancer Audit Pilot (ECAP), further expenditure on the Webinar educational programme, funding of 2 consensus meetings and funding of an additional sub-group. In 2020 Council agreed to additional spending to support the Trainees/Trainers Annual Summit, discounted registration fees to support nurse members attending Annual Scientific Meeting, increased expenditure on prizes, awards, travel fellowships and research/audit grants.

FUTURE PLANS

During 2026, the BGCS intends to continue and develop its activities, including:

- Holding the Annual Scientific Meeting in Bristol in June 2026.
- Electing the Society's first Vice President under the revised governance structure.
- Continuing development of the cervical cancer guidelines.
- Completing the Delphi consensus process relating to HIPEC in ovarian cancer, with the intention of publishing or announcing the consensus statement before the end of 2026.
- Continuing to support trainees and subspecialty fellows and contributing to discussions regarding the future gynaecological oncology workforce.
- Continuing collaboration with the RCOG and other societies on the Surgical Skills Project.
- Continuing research grant programmes, including collaborative funding with Wellbeing of Women.
- Reviewing the Society's relationship with the International Gynaecological Cancer Society.
- Continuing regular engagement with national gynaecological cancer charities.
- Seeking funding for the development of a national vulval cancer audit.
- Continuing to develop the BGCS's role in promoting high-quality, evidence-based and equitable gynaecological cancer care throughout the United Kingdom.
- Establishment of annual multidisciplinary Vulva symposium.

The trustees consider that these activities will further the charitable objectives of the BGCS and enhance the Society's contribution to improving outcomes and care for people affected by gynaecological cancer.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes an unincorporated charity. The British Gynaecological Cancer Society is constituted under a deed adopted at the time of the inaugural meeting on the 6th October 1984 and amended on the 6th May 1988, 30th April 1994, 20th May 2004 and 21 June 2013. It is a registered charity, number 290959.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Charity constitution

The range and volume of activities undertaken by the BGCS have increased considerably in recent years. These include educational meetings, guideline development, research grants, national audits, engagement with patient charities, workforce issues, professional advocacy and collaboration with other national and international organisations.

In recognition of this increased workload, the Society agreed a resolution to amend its constitution so that the BGCS will permanently have four Officers rather than three.
The additional Officer will hold the position of Vice President and will also serve as an additional trustee of the Society. The purpose of this change is to increase the leadership and governance capacity of the Society and to distribute the increasing workload amongst a larger Officer group.

The first Vice President under the new arrangements is due to be elected in June 2026. The successful candidate will serve for two years as Vice President followed by a further two-year term as President.
The trustees believe that this change will strengthen continuity of leadership, succession planning and governance within the BGCS while providing additional capacity to support the expanding activities of the Society.

Recruitment and appointment of new trustees

The office holders of the Society (President, Hon Secretary and Hon Treasurer) have automatically held the role of Trustee since the inception of the Society in 1984. It was decided that at the summer council meeting of the society on 8th July 2015 that the society should formalise the appointment of non-executive trustees and this was ratified at the AGM of 10th July 2015. It was decided that the officers of the council as described in the constitution of the BGCS 2015 Section (3) would be joined in the role of trustees by no less than two and no more than four non-voting trustees to serve for three years. The aim of council was to seek applications from the most experienced individuals within the membership and it was envisaged that such candidates would be either nearing the end of or have retired from clinical practice. The membership was asked to self nominate for the position or nominate a colleague if they were agreeable to taking up the position, by October 31st 2015. Subsequently two individuals were identified who were approached and who both accepted the position of trustee. Their appointment was ratified at AGM of 15th May 2016. The newly appointed trustees were sent an invitation letter which directed them to background reading regarding their statutory and society responsibilities. Both trustees accepted by return of post. The first responsibility delegated to the two newly appointed trustees was the recruitment of a third non voting trustee, identified at the council meeting of 9th February 2017 and subsequently directly approached with the same invitation letter used previously. The third non-voting trustee accepted the position formally on 13th March 2017 and this appointment was ratified at the AGM on 15th June 2017, this person has now stepped down from the trustee position for personal reasons at the end of 2020. A new trustee with a non medical background and expertise in legal affairs has since been appointed.

The current constitution (2017) states in relation to trustees:-
Section 2 (Membership of the Society)

iii. Trustees
1. Trustees are required by the Charity Commission.
2. Trustees shall be recommended by Council and ratified by the AGM.
3. Trustees shall serve a minimum term of three years and this term may be renewable for up to two further terms. In certain circumstances the term may be extended by a further one year to allow for overlap and ensuring suitable candidates are in post to provide continuity to the Society.
4. There shall be a minimum of 2 and a maximum of 4 trustees who will not have voting rights.
5. Trustees shall be individuals whose qualifications and motivation would be of value to the BGCS in promoting its goals within the rules of its charitable status.

Risk management

The trustees have a duty to identify and review the risks to which the Charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Overall Performance

Overall, the trustees consider that the BGCS continued to achieve its charitable objectives successfully during 2025.
The Society remains a thriving multidisciplinary organisation with an expanding role in education, research, guideline development, clinical audit, professional training, workforce planning and advocacy for high-quality gynaecological cancer care.
The successful Annual Scientific Meeting, dedicated meetings for trainees and Unit Gynaecologists, continued research funding, publication of the national endometrial cancer audit, development of clinical guidelines and consensus work, and increasing collaboration with professional bodies and patient charities demonstrate the breadth of the Society's activities.
The trustees recognise that the increasing activities of the Society also create additional governance and administrative responsibilities. The constitutional changes agreed during the year are intended to ensure that the Society has an appropriate leadership structure to support this growth.
The BGCS will continue to work with its members, the Royal College of Obstetricians and Gynaecologists, other professional societies, patient charities and national organisations to improve the diagnosis, treatment and care of people affected by gynaecological cancer.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number
290959

Principal address
Glaslyn
Ffordd Y Parc
Parc Menai
Bangor
Gwynedd
LL57 4FE

Trustees
Mr S C Leeson (appointed 29.1.26)
Mr C Chan (resigned 1.1.26)
Professor J Shepherd (resigned 1.1.26)
Ms B Rai
Mr S Dobbs (resigned 10.7.25)
Mr A J Phillips - (Secretary)
Mr K B Gajjar (resigned 10.7.25)
Dr N D G Ratnavelu - (Treasurer) (appointed 11.7.25)
T E J Ind - (President) (appointed 10.7.25)
Prof M Wells (appointed 29.1.26)
Dr N J Wood (appointed 24.6.26)

Independent Examiner
Colin Bell FCCA
Williams Denton Cyf
Chartered Certified Accountants
Glaslyn
Ffordd y Parc
Parc Menai
Bangor
Gwynedd
LL57 4FE

Approved by order of the board of trustees on 29 September 2026 and signed on its behalf by:

T E J Ind - Trustee

Independent examiner's report to the trustees of British Gynaecological Cancer Society
I report to the charity trustees on my examination of the accounts of British Gynaecological Cancer Society (the Trust) for the year ended 31 December 2025.

Responsibilities and basis of report
As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act.

Independent examiner's statement
Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Association of Chartered Certified Accountants, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Colin Bell FCCA

Williams Denton Cyf
Chartered Certified Accountants
Glaslyn
Ffordd y Parc
Parc Menai
Bangor
Gwynedd
LL57 4FE

Date: 12/10/2026.

BRITISH GYNAECOLOGICAL CANCER SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2025

	Notes	Unrestricted fund £	Restricted funds £	**2025 Total funds £**	2024 Total funds £
INCOME AND ENDOWMENTS FROM					
Charitable activities	3				
To advance the science and art of gynaecological oncology for the benefit of the public		**499,508**	**27,500**	**527,008**	403,115
Investment income	2	**6,655**	**-**	**6,655**	9,738
Total		**506,163**	**27,500**	**533,663**	412,853
EXPENDITURE ON					
Charitable activities	4				
To advance the science and art of gynaecological oncology for the benefit of the public		**578,864**	**65,520**	**644,384**	502,229
NET INCOME/(EXPENDITURE)		**(72,701)**	**(38,020)**	**(110,721)**	(89,376)
Transfers between funds	11	**(24,660)**	**24,660**	**-**	**-**
Net movement in funds		**(97,361)**	**(13,360)**	**(110,721)**	(89,376)
RECONCILIATION OF FUNDS					
Total funds brought forward		**532,863**	**13,360**	**546,223**	635,599
TOTAL FUNDS CARRIED FORWARD		**435,502**	**-**	**435,502**	546,223

CONTINUING OPERATIONS
All income and expenditure has arisen from continuing activities.

The notes form part of these financial statements

BALANCE SHEET
31 DECEMBER 2025

	Notes	Unrestricted fund £	Restricted funds £	2025 Total funds £	2024 Total funds £
CURRENT ASSETS					
Debtors	9	**129,963**	-	**129,963**	123,959
Cash at bank		**421,558**	-	**421,558**	515,278
		551,521	-	**551,521**	639,237
CREDITORS					
Amounts falling due within one year	10	**(116,019)**	-	**(116,019)**	(93,014)
NET CURRENT ASSETS		**435,502**	-	**435,502**	546,223
TOTAL ASSETS LESS CURRENT LIABILITIES		**435,502**	-	**435,502**	546,223
NET ASSETS		**435,502**	-	**435,502**	546,223
FUNDS	11				
Unrestricted funds				**435,502**	532,863
Restricted funds				-	13,360
TOTAL FUNDS				**435,502**	546,223

The financial statements were approved by the Board of Trustees and authorised for issue on 29 September 2026 and were signed on its behalf by:

T E J Ind - Trustee

The notes form part of these financial statements

BRITISH GYNAECOLOGICAL CANCER SOCIETY

CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2025

	Notes	2025 £	2024 £
Cash flows from operating activities			
Cash generated from operations	1	**(100,375)**	(41,303)
Net cash used in operating activities		**(100,375)**	(41,303)
Cash flows from investing activities			
Interest received		**6,655**	9,738
Net cash provided by investing activities		**6,655**	9,738
Change in cash and cash equivalents in the reporting period		**(93,720)**	(31,565)
Cash and cash equivalents at the beginning of the reporting period		**515,278**	546,843
Cash and cash equivalents at the end of the reporting period		**421,558**	515,278

The notes form part of these financial statements

NOTES TO THE CASH FLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2025

1. RECONCILIATION OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2025	2024
	£	£
Net expenditure for the reporting period (as per the Statement of Financial Activities)	**(110,721)**	(89,376)
Adjustments for:		
Interest received	**(6,655)**	(9,738)
Increase in debtors	**(6,003)**	(29,365)
Increase in creditors	**23,004**	87,176
Net cash used in operations	**(100,375)**	(41,303)

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.1.25	Cash flow	At 31.12.25
	£	£	£
Net cash			
Cash at bank	**515,278**	**(93,720)**	**421,558**
	515,278	**(93,720)**	**421,558**
Total	**515,278**	**(93,720)**	**421,558**

The notes form part of these financial statements

1. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income
Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from Government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

Expenditure and irrecoverable vat
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Irrecoverable VAT is charged as a cost in the statement of financial activities.

Taxation
The charity is exempt from corporation tax on its charitable activities and is registered for VAT purposes.

Fund accounting
Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

2. INVESTMENT INCOME

	2025	2024
	£	£
Deposit account interest	6,655	9,738

continued...

3. INCOME FROM CHARITABLE ACTIVITIES

	Activity	2025 £	2024 £
Grants	To advance the science and art of gynaecological oncology for the benefit of the public	**27,500**	62,500
Sponsorships	To advance the science and art of gynaecological oncology for the benefit of the public	**1,500**	833
Delegate fees	To advance the science and art of gynaecological oncology for the benefit of the public	**16,275**	17,391
Subscriptions	To advance the science and art of gynaecological oncology for the benefit of the public	**63,024**	56,038
ASM Social Programme	To advance the science and art of gynaecological oncology for the benefit of the public	**11,653**	8,230
ASM Delegate income	To advance the science and art of gynaecological oncology for the benefit of the public	**161,439**	137,110
ASM Sponsorship income	To advance the science and art of gynaecological oncology for the benefit of the public	**245,617**	120,863
Sundry income	To advance the science and art of gynaecological oncology for the benefit of the public	**-**	150
		527,008	403,115

Grants received, included in the above, are as follows:

	2025 £	2024 £
Merck Sharp & Dohme (Endometrical Cancer Audit)	**-**	30,000
GlaxoSmithKline (Endometrial Cancer Audit)	**-**	20,000
Eisai Ltd (Endometrial Cancer Audit)	**5,000**	5,000
British Assoc. of Gynaecological Pathologists (Endometrial Cancer Audit)	**7,500**	7,500
Eve Appeal (Endometrial Cancer Audit)	**10,000**	-
Peaches Womb Cancer Trust (Endometrial Cancer Audit)	**5,000**	-
	27,500	62,500

continued...

4. CHARITABLE ACTIVITIES COSTS

	Direct Costs	Support costs (see note 5)	Totals
	£	£	£
To advance the science and art of gynaecological oncology for the benefit of the public	**595,651**	**48,733**	**644,384**

5. SUPPORT COSTS

	Management	Governance costs	Totals
	£	£	£
To advance the science and art of gynaecological oncology for the benefit of the public	**36,785**	**11,948**	**48,733**

6. INDEPENDENT EXAMINER'S FEES

	2025	2024
	£	£
Independent examiner's fees	**2,645**	2,500

7. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2025 nor for the year ended 31 December 2024.

Trustees' expenses

	2025	2024
	£	£
Trustees' expenses	**3,876**	5,979

8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund	Restricted funds	Total funds
	£	£	£
INCOME AND ENDOWMENTS FROM			
Charitable activities			
To advance the science and art of gynaecological oncology for the benefit of the public	340,615	62,500	403,115
Investment income	9,738	-	9,738
Total	350,353	62,500	412,853
EXPENDITURE ON			

continued...

8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued

	Unrestricted fund £	Restricted funds £	Total funds £
Charitable activities			
To advance the science and art of gynaecological oncology for the benefit of the public	453,089	49,140	502,229
NET INCOME/(EXPENDITURE)	(102,736)	13,360	(89,376)
RECONCILIATION OF FUNDS			
Total funds brought forward	635,599	-	635,599
TOTAL FUNDS CARRIED FORWARD	532,863	13,360	546,223

9. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025 £	2024 £
Other debtors	**98,861**	67,313
VAT	**-**	5,566
Prepayments	**31,102**	51,080
	129,963	123,959

10. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025 £	2024 £
VAT	**7,989**	-
Other creditors	**61,340**	46,759
Deferred income	**44,045**	43,755
Accrued expenses	**2,645**	2,500
	116,019	93,014

continued...

11. MOVEMENT IN FUNDS

	At 1.1.25 £	Net movement in funds £	Transfers between funds £	At 31.12.25 £
Unrestricted funds				
General fund	**532,863**	**(72,701)**	**(24,660)**	**435,502**
Restricted funds				
Endometrial Cancer Audit	**13,360**	**(38,020)**	**24,660**	**-**
TOTAL FUNDS	**546,223**	**(110,721)**	**-**	**435,502**

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	**506,163**	**(578,864)**	**(72,701)**
Restricted funds			
Endometrial Cancer Audit	**27,500**	**(65,520)**	**(38,020)**
TOTAL FUNDS	**533,663**	**(644,384)**	**(110,721)**

Comparatives for movement in funds

	At 1.1.24 £	Net movement in funds £	At 31.12.24 £
Unrestricted fund	635,599	(102,736)	532,863
Restricted funds			
Endometrial Cancer Audit	-	13,360	13,360
TOTAL FUNDS	635,599	(89,376)	546,223

continued...

11. MOVEMENT IN FUNDS - continued

Comparative net movement in funds included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted fund	350,353	(453,089)	(102,736)
Restricted funds			
Endometrial Cancer Audit	62,500	(49,140)	13,360
TOTAL FUNDS	412,853	(502,229)	(89,376)

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.24 £	Net movement in funds £	Transfers between funds £	At 31.12.25 £
Unrestricted fund	635,599	(175,437)	(24,660)	435,502
Restricted funds				
Endometrial Cancer Audit	-	(24,660)	24,660	-
TOTAL FUNDS	635,599	(200,097)	-	435,502

Net movement in funds included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted fund	856,516	(1,031,953)	(175,437)
Restricted funds			
Endometrial Cancer Audit	90,000	(114,660)	(24,660)
TOTAL FUNDS	946,516	(1,146,613)	(200,097)

Purpose of the Restricted Funds

Endometrial Cancer Audit
The BGCS have commissioned a two year retrospective audit into the incidence, mortality and treatment of Endometrial cancer in the UK. The Endometrial Cancer Audit Project (ECAP) has been co-funded by BGCS and other charities as well as receiving grants from some pharmaceutical companies.The project will aid the Gynaecological cancer community in planning appropriate treatment and also assess if there are regional variations in the management of endometrial cancer within the UK

continued...

12. RELATED PARTY DISCLOSURES

Due to the nature of the charity's operations and composition of the board of trustees and membership both trustees and members will pay subscriptions and fees to the Charity, other than these no material transactions have been identified which should be disclosed.